​

GeneDx (WGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WGS Stock Forecast

GeneDx (WGS) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $162.50, with a high of $200.00 and a low of $120.00. This represents a 4.60% increase from the last price of $155.36.

- $40 $80 $120 $160 $200 High: $200 Avg: $162.5 Low: $120 Last Closed Price: $155.36

WGS Stock Rating

GeneDx stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (81.82%), 2 Hold (18.18%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 2 9 Strong Sell Sell Hold Buy Strong Buy

WGS Price Target Upside V Benchmarks

TypeNameUpside
StockGeneDx4.60%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Information Services Stocks 23.76%

Price Target Trends

1M3M12M
# Anlaysts156
Avg Price Target$200.00$170.00$161.67
Last Closing Price$155.36$155.36$155.36
Upside/Downside28.73%9.42%4.06%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25171--9
Nov, 25171--9
Oct, 25161--8
Sep, 25151--7
Aug, 25151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2025BTIG$200.00$155.3628.73%28.73%
Oct 29, 2025BTIG$165.00$137.4020.09%6.20%
Oct 29, 2025Canaccord Genuity$160.00$137.4716.39%2.99%
Oct 29, 2025Guggenheim$170.00$137.4723.66%9.42%
Oct 20, 2025Canaccord Genuity$155.00$120.9428.16%-0.23%
Aug 04, 2025Piper Sandler$120.00$108.3510.75%-22.76%
Oct 24, 2024Bill BonelloCraig-Hallum$70.00$58.0020.69%-54.94%
Aug 27, 2024Brandon CouillardWells Fargo$34.00$35.35-3.82%-78.12%
Jul 31, 2024Mark MassaroBTIG$45.00$30.1349.35%-71.04%
Jul 10, 2024Bill BonelloCraig-Hallum$43.00$29.8144.25%-72.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 12, 2025BTIGBuyBuyhold
Oct 29, 2025BTIGBuyBuyhold
Oct 29, 2025GuggenheimBuyBuyhold
Sep 11, 2025Piper SandlerOverweightOverweighthold
Aug 04, 2025Piper SandlerOverweightOverweighthold
Jun 30, 2025GuggenheimBuyBuyhold
May 15, 2025GuggenheimBuyinitialise
Jan 07, 2025Cowen & Co.BuyBuyhold
Oct 29, 2024Wells FargoEqual-WeightEqual-Weighthold
Oct 29, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-74.93$-53.63$-7.23$-1.94---
Avg Forecast$-34.54$-29.04$-5.35$-0.27$0.55$1.46$2.68
High Forecast$-34.00$-28.74$-5.26$-0.26$0.56$2.17$2.75
Low Forecast$-35.31$-29.45$-5.49$-0.27$0.54$0.74$2.63
Surprise %116.94%84.68%35.14%618.52%---

Revenue Forecast

$150M $220M $290M $360M $430M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$212.19M$234.69M$202.57M$305.45M---
Avg Forecast$203.77M$244.28M$192.76M$290.22M$338.77M$398.42M$476.30M
High Forecast$207.25M$246.90M$196.45M$295.78M$345.27M$406.06M$485.43M
Low Forecast$201.34M$242.35M$190.23M$286.41M$334.33M$393.20M$470.05M
Surprise %4.14%-3.92%5.09%5.25%---

Net Income Forecast

$-900M $-700M $-500M $-300M $-100M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-245.39M$-548.98M$-175.77M$-52.29M---
Avg Forecast$-839.74M$-706.04M$-130.66M$-6.47M$13.36M$35.41M$65.16M
High Forecast$-826.71M$-698.78M$-127.93M$-6.33M$13.64M$52.75M$66.78M
Low Forecast$-858.41M$-715.90M$-133.39M$-6.60M$13.08M$18.08M$64.05M
Surprise %-70.78%-22.25%34.52%708.38%---

WGS Forecast FAQ

Is GeneDx stock a buy?

GeneDx stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GeneDx is a favorable investment for most analysts.

What is GeneDx's price target?

GeneDx's price target, set by 11 Wall Street analysts, averages $162.5 over the next 12 months. The price target range spans from $120 at the low end to $200 at the high end, suggesting a potential 4.60% change from the previous closing price of $155.36.

How does GeneDx stock forecast compare to its benchmarks?

GeneDx's stock forecast shows a 4.60% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the healthcare information services stocks industry (23.76%).

What is the breakdown of analyst ratings for GeneDx over the past three months?

  • December 2025: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is GeneDx’s EPS forecast?

GeneDx's average annual EPS forecast for its fiscal year ending in December 2025 is $0.55, marking a -128.35% decrease from the reported $-1.94 in 2024. Estimates for the following years are $1.46 in 2026, and $2.68 in 2027.

What is GeneDx’s revenue forecast?

GeneDx's average annual revenue forecast for its fiscal year ending in December 2025 is $338.77M, reflecting a 10.91% increase from the reported $305.45M in 2024. The forecast for 2026 is $398.42M, and $476.3M for 2027.

What is GeneDx’s net income forecast?

GeneDx's net income forecast for the fiscal year ending in December 2025 stands at $13.36M, representing a -125.56% decrease from the reported $-52.286M in 2024. Projections indicate $35.41M in 2026, and $65.16M in 2027.